{
  "id": 5106399,
  "title": "Alteogen Signs Up to $3.22 Billion Licensing Deal With Novartis",
  "url": "https://urgent.news/2026/09/02/alteogen-signs-up-to-3-22-billion-licensing-deal-with-novartis",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-02T14:46:32.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=276052"
  },
  "original_language": "en",
  "account": "Alteogen has inked a significant licensing deal with pharmaceutical behemoth Novartis, demonstrating the global prowess of its proprietary ALT-B4 technology for transforming intravenous drugs into subcutaneous formulations. The agreement, signed on September 2, grants Novartis exclusive rights to develop and market SC versions of its biologic drugs using Alteogen's ALT-B4 platform. If all options are taken advantage of and development milestones are met, Alteogen could receive up to $3.22 billion, or approximately 4.42 trillion won. This deal marks Alteogen's fourth licensing agreement this year, with the company's cumulative maximum value of licensing deals surpassing $4.45 billion. In addition to milestone payments, Alteogen will also receive royalties based on the net sales of products using ALT-B4 after commercialization. The technology, which involves temporarily breaking down hyaluronan beneath the skin to enhance drug diffusion and absorption, is pivotal to the deal. Alteogen CEO Jeon Tae-yeon highlighted the company's evaluation of ALT-B4 applications across various modalities prior to signing with Novartis, emphasizing the Hybrozyme platform's technological and commercial potential. As global pharma firms strive for SC formulations to boost patient convenience and shorten administration times, Alteogen's platform technology is poised to see increased market interest. The Novartis agreement is Alteogen's second-largest deal to date, further underscoring the technological capabilities of South Korea's biotechnology industry on the global stage.",
  "summary": "Alteogen has secured a landmark licensing deal with global pharmaceutical giant Novartis, underscoring the global competitiveness of its proprietary platform technology for converting intravenous drugs into subcutaneous formulations.Alteogen said on Sept. 2 that it had signed an option and licensing",
  "key_points": [
    "Alteogen signs $3.22B licensing deal with Novartis on September 2",
    "Novartis gets exclusive rights to develop SC versions of biologics using ALT-B4 platform",
    "Deal could bring up to $3.22B to Alteogen, with royalties on net sales"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}